JY
JSPR icon

Jeff Yass’s Jasper Therapeutics JSPR Stock Holding History

Jeff Yass’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33K Buy
+10,300
New +$7.71K ﹤0.01% 13199
2026
Q1 		– Sell
-10,300
Closed -$18.8K – 13643
2025
Q4 		$18.8K Sell
10,300
-15,600
-60% -$31.3K ﹤0.01% 11975
2025
Q3 		$61.6K Sell
25,900
-9,900
-28% -$30K ﹤0.01% 11793
2025
Q2 		$199K Buy
+35,800
New +$176K ﹤0.01% 11214
2025
Q1 		– Sell
-21,700
Closed -$464K – 12998
2024
Q4 		$464K Sell
21,700
-50,400
-70% -$1.05M ﹤0.01% 8856
2024
Q3 		$1.36M Buy
72,100
+39,400
+120% +$784K ﹤0.01% 6136
2024
Q2 		$742K Buy
32,700
+18,800
+135% +$451K ﹤0.01% 7282
2024
Q1 		$408K Buy
+13,900
New +$247K ﹤0.01% 8992
2023
Q2 		– Sell
-1,130
Closed -$20.5K – 12642
2023
Q1 		$20.5K Buy
+1,130
New +$20.9K ﹤0.01% 12044

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's JSPR Position: Q2 2026 in Review

Jeff Yass sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 11,149 shares — an estimated $8.35K sold.

Jeff Yass first reported a position in JSPR in Q4 2022 and held it in 10 quarters. The position peaked at $488K in Q4 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Jeff Yass reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 11,149 Jasper Therapeutics shares in Q2 2026, an estimated $8.35K.
  • Jeff Yass first reported a position in Jasper Therapeutics in Q4 2022 and held it in 10 quarters.
  • Jeff Yass's Jasper Therapeutics position peaked at $488K in Q4 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.